We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+50.7%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.36B
AUM Growth
+$330M
Cap. Flow
-$51.5M
Cap. Flow %
-3.79%
Top 10 Hldgs %
77.83%
Holding
43
New
3
Increased
11
Reduced
10
Closed
9
Avg Time Held
4.6 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$63.4M
2
SRRK icon
Scholar Rock
SRRK
+$49.4M
3
ANNX icon
Annexon
ANNX
+$14.3M
4
IMNM icon
Immunome
IMNM
+$12.2M
5
RAPT icon
RAPT Therapeutics
RAPT
+$10.4M

Top Sells

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$70.1M
2
LIVN icon
LivaNova
LIVN
+$46.2M
3
AKRO icon
Akero Therapeutics
AKRO
+$35.5M
4
COGT icon
Cogent Biosciences
COGT
+$21.7M
5
ETNB icon
89bio
ETNB
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CLDX icon
26
Celldex Therapeutics
CLDX
$2.27B
$7.69M 0.57%
283,308
-43,700
-13% -$1.15M
2020 Q2
22 quarters
LIVN icon
27
LivaNova
LIVN
$4.32B
$7.26M 0.53%
118,054
-808,745
-87% -$46.2M
2021 Q1
19 quarters
IVVD icon
28
Invivyd
IVVD
$197M
$6.62M 0.49%
2,681,159
+395,839
+17% +$823K
2021 Q3
17 quarters
XENE icon
29
Xenon Pharmaceuticals
XENE
$3.32B
$6M 0.44%
+133,882
New +$5.62M
2025 Q4
0 quarters
RPTX icon
30
DELISTED
Repare Therapeutics
RPTX
$4.12M 0.3%
1,586,174
– –
2020 Q2
22 quarters
ALXO icon
31
ALX Oncology
ALXO
$138M
$3.69M 0.27%
3,264,718
-68,265
-2% -$103K
2020 Q3
21 quarters
ORIC icon
32
Oric Pharmaceuticals
ORIC
$1.32B
$3.67M 0.27%
+448,110
New +$5.16M
2025 Q4
0 quarters
PLRX icon
33
Pliant Therapeutics
PLRX
$60.2M
$1.97M 0.15%
1,616,228
+24,533
+2% +$36.9K
2020 Q2
22 quarters
KLRS icon
34
Kalaris Therapeutics
KLRS
$52.1M
$700K 0.05%
82,955
– –
2020 Q3
21 quarters
AKRO icon
35
DELISTED
Akero Therapeutics
AKRO
– –
-747,818
Closed -$35.5M –
ETNB icon
36
DELISTED
89bio
ETNB
– –
-1,473,136
Closed -$21.7M –
FOLD icon
37
DELISTED
Amicus Therapeutics
FOLD
– –
-777,178
Closed -$6.12M –
KROS icon
38
Keros Therapeutics
KROS
$220M
– –
-552,506
Closed -$8.74M –
LVTX icon
39
DELISTED
LAVA Therapeutics
LVTX
– –
-2,074,372
Closed -$3.24M –
PRME icon
40
Prime Medicine
PRME
$655M
– –
-87,118
Closed -$483K –
VTYX icon
41
DELISTED
Ventyx Biosciences
VTYX
– –
-1,073,386
Closed -$3.34M –
XERS icon
42
Xeris Biopharma Holdings
XERS
$1.84B
– –
-451,099
Closed -$3.67M –
BOLD icon
43
Boundless Bio
BOLD
$54.3M
– –
-245,458
Closed -$302K –
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2025 Portfolio in Review

As of Q4 2025, Redmile Group held 43 positions worth $1.36B, up 32% from $1.03B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Redmile Group withdrew a net $51.5M in Q4 2025, closing 9 positions and reducing 10 holdings. Its most notable exit was Akero Therapeutics, an estimated $35.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in DBV Technologies S.A. American Depositary Shares worth $10.5M.

  • Redmile Group's largest Q4 2025 buy was DBV Technologies S.A. American Depositary Shares: 549,840 shares worth $10.5M.
  • Redmile Group added most to Nurix Therapeutics in Q4 2025, an estimated $63.4M increase.
  • Redmile Group's biggest Q4 2025 reduction was Zymeworks, cutting an estimated $70.1M.
  • Redmile Group fully exited Akero Therapeutics in Q4 2025, selling an estimated $35.5M.
  • Redmile Group's ten largest holdings make up 78% of its $1.36B portfolio in Q4 2025.
  • Redmile Group opened 3 new positions and closed 9 in Q4 2025.
  • Redmile Group's portfolio value rose 32% quarter-over-quarter to $1.36B.

Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.